Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, Inc. (NASDAQ:DYN), filed a Form 4 on August 17, 2026, reporting an automatic sale of 226 shares of common stock on August 13, 2026, to satisfy tax withholding obligations tied to vesting restricted stock units.

Key Highlights

  • Transaction date: 226 shares of Dyne Therapeutics common stock were disposed of on August 13, 2026.
  • Weighted average price: Shares were sold at a weighted average price of $26.28, within a range of $26.17 to $26.39.
  • Purpose: The sale was automatic, executed to satisfy tax withholding obligations upon the vesting of restricted stock units granted on February 12, 2026.
  • Rule 10b5-1 plan: The sale was made pursuant to a binding contract consistent with the affirmative defense conditions of Rule 10b5-1(c) and, according to the filing, "does not represent a discretionary trade by the Reporting Person."
  • Beneficial ownership after transaction: Friedl-Naderer directly holds 153,982 shares following the reported transaction, including 119,928 unvested RSUs.

Dyne Therapeutics CCO's RSU Vesting Prompts Automatic Share Sale

According to the Form 4 filed with the Securities and Exchange Commission, Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, Inc., disposed of 226 shares of common stock on August 13, 2026. The filing states the shares were "automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026."

The filing indicates the sale was carried out under a restricted stock unit agreement constituting a "binding contract" consistent with Rule 10b5-1(c). The shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive, with $26.28 reported as the weighted average price. The filing notes that full details of the number of shares sold at each separate price are available upon request to the issuer, any security holder, or the SEC staff.

Following the reported transaction, Friedl-Naderer beneficially owns 153,982 shares of Dyne Therapeutics common stock on a direct basis. The filing discloses that 119,928 of those shares represent unvested RSUs. No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Dan Wilson as Attorney-in-Fact and filed on August 17, 2026.

What Was Disclosed

Dyne Therapeutics Chief Commercial Officer Johanna Friedl-Naderer reported an automatic sale of 226 common shares at a weighted average price of $26.28 on August 13, 2026, solely to cover tax withholding on vesting RSUs, leaving her with 153,982 shares beneficially owned.